EP Patent

EP4574214A2 — Cyclic compounds and methods of using same

Assigned to Schroedinger Inc · Expires 2025-06-25 · 1y expired

What this patent protects

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, an…

USPTO Abstract

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for inhibiting kinase activity, and for treating cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP4574214A2
Jurisdiction
EP
Classification
Expires
2025-06-25
Drug substance claim
No
Drug product claim
No
Assignee
Schroedinger Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.